Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BetterLife Pharma ( (TSE:BETR) ) just unveiled an update.
BetterLife Pharma has announced the conversion of convertible debentures into 642,329 common shares and share purchase warrants, reflecting a total of $64,232.88. This move is part of their strategy to strengthen their financial position and advance the development of their key compounds, BETR-001 and BETR-002, which target significant unmet needs in neuro-psychiatric and neurological disorders.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing compounds to treat neuro-psychiatric and neurological disorders. Their primary products include BETR-001, a non-hallucinogenic LSD derivative, and BETR-002, based on honokiol for anxiety-related disorders. They also have a drug candidate for viral infections.
YTD Price Performance: -12.00%
Average Trading Volume: 23,025
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.11M
See more insights into BETR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue